Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gray Market Investigation Could Push Track-and-Trace Debate

This article was originally published in The Pink Sheet Daily

Executive Summary

Rep. Cummings and Sen. Rockefeller suggest serialization is not an adequate replacement for state pedigree laws in letter to House and Senate leaders conferencing on user fee bills.

You may also be interested in...



FDA Relies On Fax Machine For Messages About Unreliable Drugs

“Know Your Source” campaign material will be sent to providers through same medium as offers from questionable wholesalers.

Track-and-Trace Law: Push Begins For 2015 Exchange Standards

FDA has a tight deadline to finalize guidance on transaction information.

Track And Trace System Could Start With RxTEC As Foundation, FDA Says

Compromise proposal from agency would allow lot-level tracking at first, if there was a “clear path” to a more advanced system in subsequent years.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS074271

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel